Nitrazepate is the diazepam derivative. Nitrazepate is tranquiliser.

Naveglitazar is an oral dual peroxisome proliferator-activated receptor (PPAR) agonist, which was under development with Ligand Pharmaceuticals for the treatment of type 2 diabetes mellitus. Naveglitazar is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models and in the clinic. Naveglitazar had been in phase II clinical trials for the once-daily oral treatment of type 2 diabetes, however, the development was discontinued.

Demecycline is a tetracycline antibiotic drug. Tetracyclines have a broad spectrum of anti-microbial activity and act by interfering with bacterial protein synthesis. Demecycline is used to treat a wide range of infections caused by bacteria. Some of these infections are: Severe acne; Infections of the brain and liver caused by the bacteria Leptospira; Infection caused by Brucella bacteria (brucellosis); Infections caused by Rickettsiae micro-organisms transmitted by lice, fleas, ticks and mites; Infections of the sex organs and organs associated with urination (genito-urinary infections) such as an infection called chancroid, non-gonococcal urethritis; Rare infections such as Tularaemia and bubonic plague. The following undesirable effects have been reported for demecycline: loss of appetite, nausea, vomiting, diarrhea, inflammation of the tongue, difficulty in swallowing, intestinal inflammation, and inflammatory lesions, rashes, redness of the skin, pigmentation, sensitivity to light, acute kidney failure and others.

Mecloqualone is a quinazoline-class GABAergic and an analog of methaqualone. It acts as an agonist of the beta subtype of GABAa receptor and induces sedative, hypnotic and anxiolytic effects. Mecloqualone was marketed (mostly in france) under the names Nubrene and Casfen for the treatment of insomnia. Mecloqualone is no longer prescribed because of concerns about its potential for abuse and overdose. In the United States, it is registered as a Schedule-I non-narcotic controlled substance.

Bamnidazole was developed as an antiprotozoal agent against Tryhomonas, however, has never been marketed.

Iniparib (BSI-201 or 4-iodo-3-nitrosobenzamide) inactivated poly(ADP-ribose) polymerase by zinc ejection from the first zinc finger of this nuclear protein. Iniparib, either alone or in combination with chemotherapy, had significant antitumor activity in preclinical studies in vitro and in vivo. In June 2013, Sanofi dropped the drug after it failed in a phase III trial of patients with squamous non–small-cell lung cancer and a phase II trial in platinum-resistant ovarian cancer.

Daxalipram is a selective inhibitor of phosphodiesterase (PDE) 4B.This compound is an R-isomer of mesopram and is known as (R)-mesopram. Mesopram is known to trigger ovulation and exhibits efficacy against experimental autoimmune encephalomyelitis and murine colitis in vivo. Moreover, is used in compositions for the treatment or prevention of respiratory inflammation.

Apadenoson (BMS-068645) is a selective adenosine 2A agonist that contains a methyl ester group which undergoes esterase hydrolysis to its acid metabolite. Apadenoson had been in phase III clinical trials by Forest (now a part of Allergan) for the treatment of coronary artery disease. However, this study has been terminated.

Becocalcidiol is a vitamin D analog participated in phase II clinical trials as a topical treatment for psoriasis. Therapy was safe and well tolerated, however further studies were discontinued.

Leucocianidol is a vasoprotector. It increases the resistance of vessels and decreases their permeability. Leucocianidol increases the tonicity of the veins. Leucocianidol is used in the management of capillary fragility, hemorrhoids, venolymphatic insufficiency. In combination with lidocaine and hydrocortisone, it is used in the symptomatic treatment of hemorrhoidal crisis. Leucocianidol inhibits 12-lipoxygenase.